Zhou AP, et al. - For patients with metastatic renal cell carcinoma (mRCC), researchers tested the safety and effectiveness of anlotinib (a tyrosine kinase inhibitor inhibiting angiogenesis) vs sunitinib as first-line treatment. In this multicenter, randomized phase 2 trial, they randomly assigned patients with mRCC from 13 clinical centers in a 2:1 ratio to receive anlotinib (n = 90) or sunitinib (n = 43). Anlotinib was administered orally once daily at a dose of 12 mg and sunitinib was administered orally at a dose of 50 mg once daily. According to findings, the clinical effectiveness of anlotinib was comparable to sunitinib as first-line treatment for mRCC, but it had a better safety profile. Hand-foot syndrome, eyelid edema, hair depigmentation, skin yellowing, neutropenia, thrombocytopenia, and anemia were adverse events seen less frequently with anlotinib.